RxDoctor Payments Data

David Rivadeneira, MD

Colon & Rectal Surgery · Woodbury, NYNPI 1457370785

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $184,500 of the $271,311 with a category attached, or 68.0%. 40 manufacturers reported payments, led by Evologics LLC at 31.3% of the total. Among colon & rectal surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$271,311in general payments, 2019–2025

Across 193 payments — averaging $1405.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Evologics LLC$85K
  • Dilon Technologies, Inc.$48K
  • Stryker$40K
  • Biom'up France SAS$32K
  • Integra Lifesciences Corporation$26K
  • Guard Medical Inc.$17K
  • plus $23K from 34 others

What the payments were for

  • Consulting fees$184,50068%
  • Speaking & faculty fees$29,00011%
  • Travel & lodging$11,2444%
  • Food & beverage$7,0733%
  • Education$190%
  • Other$39,47515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$271,311 in reported general payments places this provider in the 95th percentile of 177 colon & rectal surgery providers in New York.

See all colon & rectal surgery providers in New York

Medicare billing

Part B allowed, 2024
$403,476
Medicare patients
434
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine11$2,663
LoperamideLoperamide Hcl15$689
Neomycin Sulfate62$316
Metronidazole66$169
Hydrocortisone11$156

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Woodbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →